Beijing Hotgen Biotech Co., Ltd.

Equities

688068

CNE100003P82

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E. Other stock markets 23:00:00 27/06/2024 BST			5-day change	1st Jan Change
25.83 ^CNY	+0.43%		-4.72%	-37.08%

05-08	Tranche Update on Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback Plan announced on February 8, 2024.	CI
05-07	Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback announced on February 8, 2024, has closed with 2,893,010 shares, representing 3.24% for CNY 92.02 million.	CI

Tranche Update on Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback Plan announced on February 8, 2024.

May 08, 2024 at 05:00 pm

From April 1, 2024 to May 7, 2024, the company has repurchased 175,000 shares, representing 0.2% for CNY 4.99 million. With this, the company has completed the repurchase of 2,893,010 shares, representing 3.24% for CNY 92.02 million under the buyback announced on February 8, 2024.

Latest news about Beijing Hotgen Biotech Co., Ltd.

Tranche Update on Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback Plan announced on February 8, 2024.	05-08	CI
Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback announced on February 8, 2024, has closed with 2,893,010 shares, representing 3.24% for CNY 92.02 million.	05-06	CI
Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-29	CI
Beijing Hotgen Biotech to Buy Kaijing Gene Technology for 11 Million Yuan	04-16	MT
Tranche Update on Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback Plan announced on February 8, 2024.	04-03	CI
Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
Beijing Hotgen Biotech Co., Ltd. announces an Equity Buyback for CNY 150 million worth of its shares.	02-07	CI
Beijing Hotgen Biotech Co., Ltd. authorizes a Buyback Plan.	02-06	CI
Beijing Hotgen Biotech Co., Ltd.(XSSC:688068) dropped from S&P Global BMI Index	12-18	CI
Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	30/10/23	CI
Beijing Hotgen Biotech Co., Ltd.(XSSC:688068) added to S&P Global BMI Index	18/09/23	CI
Hangzhou Oriomics Biotechnology Co., Ltd. announced that it has received CNY 100 million in funding from Shenzhen Dachen Caizhi Venture Capital Management Co., Ltd., Tao Capital, Beijing Hotgen Biotech Co., Ltd. and other investors	10/09/23	CI
Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	29/08/23	CI
Tranche Update on Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback Plan announced on September 6, 2022.	15/06/23	CI
Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback announced on September 6, 2022 has closed with 2,861,477 shares, representing 3.12% for CNY 166.45 million.	12/06/23	CI
Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	27/04/23	CI
Tranche Update on Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback Plan announced on September 6, 2022.	06/04/23	CI
Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	27/02/23	CI
Tranche Update on Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback Plan announced on September 6, 2022.	04/01/23	CI
Beijing Hotgen Biotech Unit Secures Registration Certificate For Two Devices	22/12/22	MT
Beijing Hotgen Biotech Gets Registration Certificate for Hepatitis B Assay Kit; Shares Fall 4%	16/11/22	MT
Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	24/10/22	CI
Tranche Update on Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback Plan announced on September 6, 2022.	12/10/22	CI
Beijing Hotgen Biotech’s Board Approves Up to $43 Million Share Buyback	07/09/22	MT
Beijing Hotgen Biotech Co., Ltd. announces an Equity Buyback for CNY 300 million worth of its shares.	06/09/22	CI

Chart Beijing Hotgen Biotech Co., Ltd.

Duration

Period

More charts

Company Profile

Beijing Hotgen Biotech Co Ltd is a China-based company mainly engaged in the research and development, production and sales of in vitro diagnostic reagents and instruments. The Company's products mainly include in vitro diagnostic reagents, in vitro diagnostic instruments and biological raw materials. Its products are mainly used in clinical fields such as liver cancer, hepatitis, cardiovascular and cerebrovascular diseases, and inflammatory infections, as well as in public safety and other fields such as biosafety, food safety, and disease control and emergency response. The Company primarily conducts its businesses in domestic and overseas markets.

Sector

Medical Equipment, Supplies & Distribution

Calendar

27/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
BEIJING HOTGEN BIOTECH CO., LTD.	-37.08%	309M
ABBOTT LABORATORIES	-5.60%	181B
MEDTRONIC PLC	-4.45%	101B
BECTON, DICKINSON AND COMPANY	-4.15%	67.54B
DEXCOM, INC.	-8.63%	45.09B
CENCORA, INC.	+9.70%	44.37B
HOYA CORPORATION	+6.13%	40.7B
METTLER-TOLEDO INTERNATIONAL, INC.	+15.22%	29.85B
TERUMO CORPORATION	+14.80%	24.49B
WEST PHARMACEUTICAL SERVICES, INC.	-6.46%	23.99B

Other Medical Equipment, Supplies & Distribution